Ossification of the posterior longitudinal ligament of the spine (OPLL) is the leading cause of myelopathy in Japan and is diagnosed by ectopic bone formation in the paravertebral ligament. OPLL is a systemic high bone mass disease with a strong genetic background. To detect genes relevant to the pathogenesis of OPLL, we performed a cDNA microarray analysis of systematic gene expression profiles during the osteoblastic differentiation of ligament cells from OPLL patients (OPLL cells), patients with a disorder called ossification of yellow ligament (OYL), and non-OPLL controls together with human mesenchymal stem cells (hMSCs) after stimulating them with osteogenic differentiation medium (OS). Twenty-four genes were up-regulated during osteoblastic differentiation in OPLL cells. Zinc finger protein 145 (promyelotic leukemia zinc finger or PLZF) was one of the highly expressed genes during osteoblastic differentiation in all the cells examined. We investigated the roles of PLZF in the regulation of osteoblastic differentiation of hMSCs and C2C12 cells. Small interfering RNA-mediated gene silencing of PLZF resulted in a reduction in the expression of osteoblast-specific genes such as the alkaline phosphatase, collagen 1A1 (Col1a1), Runx2/core-binding factor 1 (Cbfa1), and osteocalcin genes, even in the presence of OS in hMSCs. The expression of PLZF was unaffected by the addition of bone morphogenetic protein 2 (BMP-2), and the expression of BMP-2 was not affected by PLZF in hMSCs. In C2C12 cells, overexpression of PLZF increased the expression of Cbfa1 and Col1a1; on the other hand, the overexpression of CBFA1 did not affect the expression of Plzf. These findings indicate that PLZF plays important roles in early osteoblastic differentiation as an upstream regulator of CBFA1 and thereby might participate in promoting the ossification of spinal ligament cells in OPLL patients.
Ossification of the posterior longitudinal ligament of the spine (OPLL) 1 is a common hyperostotic disorder among Japanese and other Asian populations with a prevalence of 2-4% of the general population (1) . OPLL patients show ectopic bone formation in the posterior longitudinal ligament, which compresses the spinal cord leading to various neurological symptoms. Despite the late onset (average age of onset is 50 years), OPLL has a strong genetic background as shown in classical epidemiological studies and by an estimate of relative risk to siblings of ϳ10 (2, 3) . Because genetic factors appear to play crucial roles in the etiology of OPLL, genetic screenings to identify susceptibility are important. To date, we have performed genetic linkage and linkage disequilibrium studies to identify the causalities of OPLL and have successfully identified collagen 11A2 (COL11A2) and collagen 6A1 (3) (4) (5) (6) . We also demonstrated that an intron 6 (Ϫ4a) polymorphism of COL11A2 affects the splicing of exon 6 in ligament cells from OPLL patients (5) . Although the identification of genetic factors of OPLL has important implications, the overall picture of the molecular pathogenesis is still unclear, mainly because a subtle biological effect of the variant is the only observation, and, therefore, the biological significance of the variant is still obscure. Accordingly, multiple approaches are needed to understand the etiology of OPLL.
One such approach is to use a cDNA microarray technique to obtain a global view of gene expression during the osteoblastic differentiation of ligament cells from OPLL patients. Genes whose expression changed markedly during osteoblastic differentiation would play key roles in the pathogenesis of OPLL. Primary ligament cells from patients with OPLL or a related disorder, ossification of yellow ligament (OYL), and from non-OPLL controls together with human mesenchymal stem cells (hMSCs) were treated with osteogenic differentiation medium (OS) to induce osteoblastic differentiation, and gene expression profiles during the differentiation were then monitored. Among the genes up-regulated during osteoblastic differentiation, we focused our attention on zinc finger protein 145, also known as the PLZF (promyelotic leukemia zinc finger) protein, to study the role of osteoblastic differentiation in hMSC and * This work was supported in part by a Research Grant for Specific Diseases from the Japan Foundation of Aging and Health of the Ministry of Public Health and Welfare and a Grant-in-Aid for scientific research from the Japanese Ministry of Education, Science, Sports, and Culture (to I. I). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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** To whom correspondence should be addressed. Tel.: 81-3-5449-5325; Fax: 81-3-5449-5764; E-mail: ituro@ims.u-tokyo.ac.jp. C2C12 cells, because PLZF is a zinc finger transcription factor that possibly regulates bone morphogenetic protein (BMP) expression (7) .
Bone formation is a complex process involving the proliferation and expansion of osteoprogenitors and/or pre-osteoblasts followed by osteoblastic differentiation, resulting in matrix maturation and mineralization. Major breakthroughs in the identification of factors involved in osteoblastic differentiation have been made in recent years, improving our understanding of the molecular basis of bone metabolism. Core-binding factor 1 (CBFA1/Runx2), a runt family polypeptide, has been shown to be a key regulator for osteoblastic differentiation (8, 9).
Recently, osterix was also identified as an essential factor of osteoblastic differentiation that acts downstream of CBFA1 (10) . CBFA1 and osterix are important for modulating the expression of osteoblast-specific genes such as collagen 1A1 (COL1A1), alkaline phosphatase (ALP), and osteocalcin (OCN) genes during osteoblastic differentiation (8, 10, 11) . On the other hand, Tob, a member of the family of antiproliferative proteins, acts inhibitory to osteoblastic differentiation by interacting with BMP/Smad signaling (12) . Members of the transforming growth factor-␤ family, including BMP-2, BMP-4, and BMP-7, induce osteoblastic differentiation through the up-regulation of CBFA1 expression (13) (14) (15) . CBFA1 is necessary but A, morphological features of OPLL, OYL, and non-OPLL cells cultured in control medium or OS for 9 days. B and C, ALP staining was performed in OPLL, OYL, and non-OPLL cells. Cells were cultured in medium with (ϩ) or without (Ϫ) OS for 9 days. ALP activity was determined by ALP staining as described in the "Experimental Procedures." The intensities of the staining were quantified using NIH image 1.62, and the data were expressed as the mean Ϯ S.D. of three measurements. not sufficient for osteogenesis, because the differentiation of C2C12 cells into mature osteoblasts cannot be induced by activation of CBFA1 (16) . Thus, transcription factors other than CBFA1 are required to activate the genetic pathways controlling osteoblastic differentiation. PLZF, which encodes a zinc finger transcription factor that contains nine Kruppel-type zinc finger domains at the carboxyl terminus, was identified along with retinoic acid receptor-␣ as being involved in acute promyelocytic leukemia (17) (18) (19) . PLZF contains a BTB/POZ domain at the amino terminus that mediates self-association and transcriptional repression through recruitment of a nuclear corepressor (20 -22) . Mice lacking Plzf display defects in limb patterning, affecting skeletal elements along the entire proximodistal axis (7) . We investigated the role of PLZF in the regulation of osteoblastic differentiation in hMSCs and C2C12 cells.
EXPERIMENTAL PROCEDURES
Chemicals and Antibodies-OS containing 0.1 M dexamethasone, 0.05 mM ascorbic acid-2-phosphate, and 10 mM ␤-glycerophosphate was purchased from Sigma. Human recombinant BMP-2 was purchased from Sigma, polyclonal anti-Runx-2 antibody was from Santa Cruz Biotechnology (Santa Cruz, CA), the monoclonal anti-PLZF antibody was from Oncogene Research Products (Boston, MA), and the polyclonal anti-collagen I antibody was from the Calbiochem-Novabiochem Corporation.
Cells and Cell Culture-hMSCs were purchased from BioWhittaker (Walkersville, MD). Primary ligament cells from patients were provided by the University of Yamaguchi and the University of Hirosaki with the approval of the institutional review boards of both institutes. Ligament tissues from the cervical spine were resected aseptically during surgical operation from OPLL, OYL, and non-OPLL (cervical spondylotic myelopathy) patients. The surrounding tissue was carefully removed under a dissecting microscope to extract the ossified lesion and avoid any possible contamination of osteogenic cells. The ligament tissues were washed with phosphate-buffered saline (PBS) several times, minced into 0.5-mm 3 pieces, and then placed in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and an antibiotic/antimycotic solution (100 units/ml penicillin, 100 g/ml streptomycin, and 250 ng/ml amphotericin B) (Sigma). Cells from the explants were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and the antibiotic/antimycotic solution. The cultured cells at 5-6 passages were used for the subsequent experiments. C2C12, a mouse pluripotent mesenchymal precursor cell line, was used for transient expression experiments.
RT-PCR Method-Total cellular RNA was extracted using TRIzol reagent according to the manufacturer's instructions (Invitrogen). RT-PCR was performed with the SuperScript one-step RT-PCR system and gene-specific primers according to the condition recommended by the manufacturer (Invitrogen). Reaction mixtures containing total RNA (500 ng of each), 0.2 mM dNTPs, 0.8 M each primer, 2 units of enzyme mixture including SuperScript II RT, platinum Taq DNA polymerase, and 1ϫ buffer with 1.2 mM MgSO 4 were kept at 50°C for 30 min and then at 94°C for 2 min, and PCR was performed. The PCR profile was 30 cycles at 94°C for 15 s, 55°C for 30 s, and 70°C for 1 min. The primers for RT-PCRs were designed based on human and mouse sequences in the GenBank TM . These sequences are listed in the supplementary table that can be found in the on-line version of this article.
Measurement of Alkaline Phosphatase Activity-Alkaline phosphatase activity was measured by histochemical analysis using a staining kit from Sigma (catalog number 85L-3R). Briefly, cells were fixed with citrate-buffered acetone for 30 s, washed with deionized water for 45 s, and incubated with an alkaline-dye mixture for 30 min at room temperature in the dark. The intensities of the signals were measured using NIH image version 1.62. Mineralization Assay-Mineralization of the extracellular matrix was evaluated by Alizarin Red S staining (Sigma). Cells were washed twice with PBS and fixed with 70% ethanol at Ϫ20°C for 1 h followed by several washes with deionized water. The cells were stained with Alizarin Red S (10 mg/ml) for 15 min at room temperature followed by incubation with PBS for 20 min according to the manufacturer's protocol.
cDNA Microarray Analysis-Primary ligament cells were cultured for 48 h in the presence or absence of OS and harvested to investigate differences in gene regulation at an early stage of differentiation. Total RNA was extracted from the cultured cells with TRIzol Reagent according to the manufacturer's directions (Invitrogen) and verified by using an RNA 6000 Nano assay with an Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA). Ten micrograms of total RNA was reverse transcribed into cDNA with cyanine 3-dCTP (Cy3) or cyanine 5-dCTP (Cy5) (PerkinElmer Life Sciences). Labeled probes were hybridized with an Agilent human 1 cDNA microarray kit (Agilent Technologies), which included 12,814 unique clones from Incyte UniGene 1 and human drug target clone sets. The microarray was scanned in both Cy3 and Cy5 channels with an Agilent DNA microarray scanner (Agilent Technologies). The raw data from the microarray assay were normalized according to the manufacturer's guidelines using Feature Extraction software from Agilent Technologies. The ratio of normalized intensity Ն 2.0 or Յ 0.5 was used to generate a list of genes with significant changes in expression during osteoblastic differentiation. Expression profile data were evaluated in duplicate experiments.
Immunoblotting Analysis-Cell extracts were resolved by SDS-PAGE. Proteins in the gel were electrophoretically transferred onto a polyvinylidene difluoride transfer membrane (Hybond-P; Amersham Biosciences). The membrane was incubated for 1 h at room temperature in TBS-T (Tris-buffered saline and 0.1% Tween 20) containing 3% skim milk to block nonspecific protein binding and then incubated at 4°C for 8 h with the primary antibody. Following four washes with TBS-T, the membrane was incubated with the peroxidase-conjugated secondary antibody. Antibody binding was visualized with an ECL Western blotting detection system (Amersham Biosciences).
Indirect Immunofluorescent Cell Staining-Cells (1 ϫ 10 4 ) cultured on coverslips were washed twice with PBS and fixed with 2% paraformaldehyde for 20 min at room temperature. After three washes with PBS, the cells were permeabilized with 0.3% Triton-X for 10 min at room temperature. The cells were treated with 3% skim milk in PBS for 30 min and then incubated for 1 h with primary antibody diluted 1:100 in PBS containing 3% skim milk. After three washes with PBS, the cells were incubated for 20 min with a Cy3-conjugated secondary antibody diluted 1:100 in PBS containing 3% skim milk. The cells were then washed three times with PBS, and immunolocalization was examined with a fluorescence microscope (Olympus, Tokyo, Japan).
RNA Interference-Small interfering RNA (siRNA) duplexes were synthesized using the Silencer TM siRNA construction kit (Ambion Inc., Austin, TX) (23) . The siRNA used in this study consisted of a 21-nucleotide sense strand and a 21-nucleotide antisense strand with a two-nucleotide overhang at the 3Ј-end. The sequences were as follows: PLZF-siRNA (1) sense, 5Ј-GGCCAACCAGAUGCGGCUGUU-3Ј starting at nucleotide 69 from the AUG start codon of the human PLZF coding sequence (GenBank TM accession number AF060568); PLZFsiRNA (2) sense, 5Ј-GAUGUUUGACAUCCUCUUCUU-3Ј starting at nucleotide 171 from the AUG start codon; PLZF-siRNA (1) antisense, 5Ј-CAGCCGCAUCUGGUUGGCCUU-3Ј; PLZF-siRNA (2) antisense, 5Ј-GAAGAGGAUCUCAAACAUCUU-3Ј; Cbfa1-siRNA (1) sense, 5Ј-GGCUGCAAGCAGUAUUUACUU-3Ј starting at nucleotide 141 from the AUG start codon of the mouse Cbfa1 coding sequence (GenBank TM accession number NM_009820); Cbfa1-siRNA (2) sense, 5Ј-GGACA-GAGUCAGAUUACAGUU-3Ј starting at nucleotide 1066 from the AUG start codon; Cbfa1-siRNA (1) antisense, 5Ј-GUAAAUACUGCUUG-CAGCCUU-3Ј; and Cbfa1-siRNA (2) antisense, 5Ј-CUGUAAUCU-GACUCUGUCCUU-3Ј. siRNA (100 nM) was introduced into hMSCs using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen). At 48 h post-transfection, the cells were analyzed with RT-PCR or immunofluorescent microscopy.
Transient Transfections-C2C12 cells were cultured on a 6-cm diameter dish at 40% confluency and transiently transfected with 3.0 g of the pSG5 expression vector (Stratagene) containing PLZF or PLZF⌬BTB cDNA. The expression vectors bearing full-length PLZF and PLZF⌬BTB cDNA clones were generously provided by Dr. Jonathan Licht (Mount Sinai School of Medicine). Forty-eight hours after transfection with Lipofectamine 2000 (Invitrogen), the cells were harvested and subjected to RT-PCR, immunoblotting, and immunohistochemistry.
RESULTS

Morphology and ALP Activity of Ligament Cells from OPLL, OYL, and Non-OPLL Patients in OS-Explant cells of minced ligament tissues from OPLL, OYL, and non-OPLL patients
were cultured and treated with OS. After treatment with OS for 9 days, morphological change from a spindle to cuboidal shape was observed for all of the cells with no distinct differences (Fig. 1A) .
A systemic hyperostosis is believed to underlie the pathogenesis of OPLL and OYL (1). Consequently, explant cells from non-ossified ligaments of OPLL, OYL, and non-OPLL patients were examined for ALP activity after OS treatment. OPLL and OYL cells showed dramatically increased levels of ALP activity after treatment with OS for 9 days, whereas ALP activity was only slightly increased in non-OPLL cells (Fig. 1, B and C) . These results demonstrate that OPLL and OYL cells have a tendency to differentiate into osteoblastic lineage cells as compared with non-OPLL cells.
cDNA Microarray Analysis of OPLL, OYL, and Non-OPLL Cells after OS Treatment-The temporal pattern of gene expression during osteoblastic differentiation at an early stage (48 h post-OS treatment) was examined with a cDNA microarray that covers 12,814 distinct cDNA sequences of human genes. A total of ϳ3000 genes were observed with positive signals in undifferentiated primary cells. As shown in Table I , 24 genes were up-regulated Ͼ2-fold in OPLL cells during osteoblastic differentiation. Twenty-four genes for OYL cells and 33 genes for non-OPLL control cells were up-regulated. Twenty genes, including those for metallothionein, ␣B-crystallin, and adrenomedullin were up-regulated Ͼ2-fold in OPLL in all the cells. Thirty-two genes were down-regulated during osteoblastic differentiation (Table II) . Several genes, such as trinucleotide repeat containing 3, tumor necrosis factor ␣-induced protein 6 (TSG-6), the hypoxia-inducible factor 1␣ subunit, and the P311 protein were down-regulated in all of the cells. Among them, TSG-6 expression after OS treatment decreased 0.25-fold for OPLL cells, 0.33-fold in OYL cells, and 0.48-fold in non-OPLL cells. The suppressive effect of TSG-6 on osteoblastic differentiation was further investigated in a separate study.
Expression of PLZF in Ligament Cells and hMSCs after OS Treatment-
The zinc finger protein 145 gene, or PLZF, was one of the most prominently up-regulated genes after the addition of OS in the cDNA microarray analysis. PLZF expression was increased 11.5-fold in OPLL cells, 13.4-fold in OYL cells, and 4.7-fold in non-OPLL cells after OS treatment (Table I) . RT-PCR analysis confirmed that the expression of PLZF was highly elevated in OPLL cells compared with that of non-OPLL cells measured at day 2 of OS treatment ( Fig. 2A) .
hMSCs exhibit pluripotent differentiation and differentiate into the osteogenic lineage in the presence of OS (24) . Total cellular RNA of hMSCs was extracted at days 0 -6 of the OS treatment, and then RT-PCR was performed. The expression of PLZF and CBFA1 was up-regulated in the early stages of osteoblastic differentiation and maintained for 6 days (Fig. 2B) . The cellular localization of PLZF in hMSCs was examined by immunofluorescence staining with anti-PLZF antibody. hMSCs treated with OS expressed high levels of PLZF, which was localized to the nuclei, whereas without OS treatment the cells did not express a detectable level of PLZF (Fig. 2C) .
Dexamethasone (Dex), a potent synthetic glucocorticoid and a component of OS, is known to promote an early stage of differentiation of progenitor cells such as bone marrow stromal cells to the osteoblastic lineage (25) . Treatment of hMSCs with 0.1 M of Dex for 48 h, the equivalent concentration in OS, promoted the expression of PLZF as well as that of osteoblastic markers such as ALP (Fig. 2, D and E) .
Effect of siRNA Targeting PLZF on Osteoblastic Differentiation in hMSCs-Two siRNAs targeting PLZF were prepared as shown under "Experimental Procedures" (26, 27) and transfected into OS-treated hMSCs with the lipofection method. Introduction of the two siRNAs targeting PLZF resulted in a down-regulation of the PLZF expression, whereas green fluorescent protein-targeted siRNA as a control did not affect the expression of PLZF (Fig. 3, A and B) . siRNA-mediated genesilencing of PLZF suppressed the expression of the osteoblastspecific genes ALP, COL1A1, and OCN as evaluated by RT-PCR and the mineralized matrix formation as evaluated by Alizarin Red staining (Fig. 3, B and C) , suggesting that PLZF has an important role in the osteoblastic differentiation. Lipoprotein lipase, a marker for adipogenic differentiation, was not expressed in this experiment (Fig. 3B) . The reduced expres- sion of CBFA1 after the gene silencing of PLZF in OS-treated hMSCs was confirmed by immunohistochemistry, indicating that PLZF might act as an upstream regulator for CBFA1 (Fig. 3D) .
BTB Domain of PLZF Is Required for Osteoblastic Differentiation-PLZF has three functional motifs, namely an Nterminal BTB domain, a C-terminal zinc finger that binds to specific DNA targets, and a second repression domain that interacts with the ETO corepressor (Fig. 4A) (28) . BTB domains are highly conserved from Drosophila to Homo sapiens and play critical roles in development, homeostasis, and oncogenesis (29) . To elucidate the functional roles of PLZF and particularly the BTB domain of PLZF in osteoblastic differentiation, C2C12, a well established mouse cell line capable of osteoblastic differentiation, was used for an overexpression experiment because hMSCs could not be efficiently transfected. C2C12 cells were transfected with a pSG5 expression vector bearing either PLZF or PLZF lacking the BTB domain (PLZF⌬BTB) cDNA, and the expression of the transcript and protein was examined (Fig. 4A ). PLZF and PLZF⌬BTB had equivalent levels of expression, and both localized in the nuclei (Fig. 4B) . Overexpression of PLZF in C2C12 cells resulted in an elevated expression of Cbfa1, Col1a1, and Ocn, whereas overexpression of PLZF⌬BTB showed no effect (Fig.  4, C and E) . Col1A1 and Alp expression, confirmed based on either immunohistochemistry or enzyme activity, was enhanced only after overexpression of the full-length PLZF (Fig. 4, D and F) . These findings indicate that the BTB domain of PLZF has a key role in osteoblastic differentiation.
Effect of PLZF on the Expression of Cbfa1 and Vice Versa-
Overexpression of PLZF in C2C12 cells promoted the expression of the Cbfa1 transcript and protein (Fig. 4, C and E) whereas that of PLZF⌬BTB did not have any effect. C2C12 cells that were overexpressed in PLZF were subjected to siRNA-mediated gene-silencing of Cbfa1 as described under "Experimental Procedures," showing that the Cbfa1 expression was completely diminished by treatment with the siRNAs and, subsequently, that Col1a1 and Ocn expressions were downregulated (Fig. 5A) . Inversely, we examined the effect of overexpression of cbfa1 on the expression of Plzf in C2C12 cells. The overexpression of cbfa1 in C2C12 cells, confirmed by its transcript and protein levels, resulted in up-regulation of Col1a1 and Ocn but did not induce the expression of Plzf (Fig. 5, B and  C) . These findings suggest that PLZF is an upstream regulator of CBFA1.
Effect of PLZF on BMP-2-induced Differentiation of hMSCs-BMP-2 plays important roles in bone formation and osteoblastic differentiation (30, 31) and, more specifically, induces CBFA1 expression (32) . Several studies have shown that BMP-2 induces the differentiation of mesenchymal stem cells or C2C12 cells into the osteoblastic lineage (32, 33) . We compared the effects of BMP-2 and OS on osteoblastic differentiation of hMSCs. The activity of ALP was enhanced by BMP-2 in a dose-dependent manner, and OS had an additive effect (Fig.  6A) . The hMSCs treated with OS for 6 days had a cuboidal morphology, whereas those treated with BMP-2 retained a spindle-type morphology, suggesting that distinct pathways of differentiation exist (Fig. 6B) . Then, PLZF expression during FIG. 4 . The BTB domain of PLZF is required for osteoblastic differentiation. A, PLZF contains discrete functional domains, including an N-terminal BTB domain, a repression domain (RD2), and a C-terminal zinc finger (ZF). B, PLZF or PLZF⌬BTB was transiently expressed in C2C12 cells, and the cells were immunostained with anti-PLZF antibodies. CV, control vector. C, C2C12 cells were transfected with PLZF or a PLZF⌬BTB expression vector (3 g each) and incubated for 48 h. RT-PCR was performed for the N-terminal PLZF (PLZF-BTB), the C-terminal PLZF (PLZF-ZF), Cbfa1, Col1A1, Ocn, and Gapdh. D, the effect of PLZF on levels of type I collagen protein. PLZF or PLZF⌬BTB protein were expressed in C2C12 cells, and the cells were immunostained with anti-type I collagen antibody followed by incubation with Cy3-conjugated anti-mouse antibodies. E and F, C2C12 cells were transfected with PLZF or PLZF⌬BTB expression vector (3 g each) and incubated for 48 h. The total protein was extracted, then Western blot analysis was performed as described in "Experimental Procedures." ALP activity was determined by ALP staining as described under "Experimental Procedures." The intensity of the staining was quantified using NIH image 1.62, and the data were expressed as the mean Ϯ S.D. for three measurements.
the BMP-2-induced osteoblastic differentiation of hMSCs was examined. BMP-2 enhanced the expression of ALP, CBFA1, COL1A1, and OCN as well as the ALP activity of hMSCs in a dose-dependent manner; however, it did not affect the expression of PLZF (Fig. 6C) . These results suggest that there should be distinct pathways of osteoblastic differentiation mediated by OS and BMP-2, respectively. DISCUSSION A bone loss disease, osteoporosis, is the opposite of OPLL and, indeed, has been observed in OPLL patients at low frequency compared with subjects of similar ages (34) . Therefore, elucidation of the molecular etiology of OPLL might permit us to develop novel therapeutic tools for osteoporosis as well. To date, the genetic approach with family and case control studies has identified COL11A2 and COL6A1 as susceptible to OPLL (3, 6) . Interestingly, extracellular matrix proteins appear to play important roles in the ossification process. Despite the finding that the disease-related variant of COL11A2 resulted in an altered splicing efficiency (5), the biological impact of the variants that leads to OPLL remains unknown.
OS treatment of ligament cells from OPLL and OYL patients led to elevated ALP activity levels as compared with OStreated cells from non-OPLL controls, reflecting the hyperostotic nature of OPLL and OYL (Fig. 1) . Therefore, the identification of genes regulated during osteoblastic induction with a cDNA microarray system would provide key etiological insights into the pathophysiology of OPLL. We identified several genes of interest that were up-regulated or down-regulated during osteoblastic differentiation (Table I and II) . PLZF, zinc finger protein 145, was one of the most prominently up-regulated genes in OPLL and OYL cells after OS treatment (Table I) . Recently, several zinc finger genes were reported to play important roles in bone formation, such as osterix (10), AJ18 (35) , and CIZ (36) . In addition, a series of zinc finger transcription factors of unknown function was identified in a cDNA microarray analysis after osteoblastic differentiation in human mesodermal progenitor cells (37) . Here, we investigated the functional significance of PLZF in osteoblastic differentiation.
PLZF belongs to the POZ/zinc-finger family of transcription factors. A study in mice lacking Plzf (Zfp145 Ϫ/Ϫ mice) showed that Plzf is essential for the patterning of the limb and the axial skeleton (7) . To examine the functional role of PLZF in osteoblastic differentiation, hMSCs were subjected to osteoblastic differentiation, and the involvement of PLZF was investigated. PLZF expression was dramatically enhanced by OS or Dex alone (Fig. 2) . Dex increases the expression of osteoblastic markers in animal and human bone marrow stromal cells in short term cultures; however, it does not induce complete osteoblastic differentiation (38, 39) . Therefore, PLZF expression appears to be an early event in osteoblastic differentiation. siRNA-mediated gene silencing of PLZF inhibited the osteoblastic differentiation of hMSCs (Fig. 3) . In turn, overexpression of PLZF in C2C12 cells led to elevated levels of Cbfa1 and other bone marker genes, and siRNA-mediated gene silencing of Cbfa1 abolished the inductions of the marker genes (Fig. 4  and 5) . These results strongly indicate that PLZF is a key regulator of osteoblastic differentiation and acts as an upstream activator of CBFA1, because overexpression of CBFA1 did not affect the expression of PLZF (Fig. 5) .
During the osteogenic process involving mesenchymal progenitors, various extrinsic factors such as Dex and cytokines regulate osteoblastic differentiation. Two major pathways for osteogenesis are recognized; one is a CBFA1-dependent pathway, and the other is CBFA1-independent. The CBFA1-inde- A, hMSCs were incubated in the presence or absence of BMP-2. Six days later, ALP activity was determined by ALP staining as described under "Experimental Procedures." B, morphological features of hMSCs cultured in the presence or absence of BMP-2 for 6 days. C, hMSCs were cultured in the presence or absence of BMP-2 (10 and 100 ng/ml). The total RNA was extracted after 72 h of treatment, and the expression of PLZF, ALP, CBFA1, COL1A1, OCN, and GAPDH mRNA was examined by RT-PCR.
pendent pathway was recently shown to involve Wnt signaling via LDL receptor-related protein 5 (LRP-5) (40) . LRP-5 signaling appears to be important for osteoblastic proliferation but not for differentiation, and it regulates bone formation according to observations in Lrp-5 null mice (41) . In general, the CBFA1-dependent pathway is believed to be closely linked with BMP signaling (32) . Because PLZF enhances the osteoblastic induction via CBFA1 and the null expression of Plzf resulted in a reduced expression of the Bmp genes in mice (7), the pathway might well be closely related with BMP signaling. We showed here that BMP-2 signals up-regulated the expression of CBFA1 but did not regulate the expression of PLZF (Fig. 6) . Also, overexpression or reduction of PLZF did not regulate BMP expression in this cell culture system (data not shown). In addition, OS-treated hMSCs showed a cuboidal morphology, whereas BMP-2-treated cells maintained a spindle-type morphology, indicating that distinct pathways are involved in the osteoblastic differentiation process in hMSCs. Recently, Nishimura et al. demonstrated that CBFA1 is able to induce osteoblastic differentiation without interacting with BMP-2 signaling molecules (42) . Taken together, it appears that PLZF acts as a promoting factor for osteoblastic differentiation stimulated by glucocorticoids via the induction of CBFA1; however, the pathway is independent of the BMP signaling pathway.
In conclusion, PLZF, identified as an up-regulated gene during the osteoblastic differentiation of OPLL cells, plays important roles in the early stage of osteoblastic differentiation in hMSCs. The molecular pathways by which PLZF exerts its function in bone formation are still under investigation, and the knowledge gained from such a study will facilitate the development of novel therapeutic tools for both bone-forming and bone loss diseases.
